uniQure Announces Pricing of its Public Offering Lexington, MA and Amsterdam, the Netherlands

Pricing of its Public Offering

Lexington, MA and Amsterdam, the Netherlands,

January 8, 2025 - uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients

with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public

offering price of $17.00 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts

and commissions and offering expenses payable by uniQure, are expected to be approximately $75 million. All securities to be sold in the

offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 661,764 additional

ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about

January 10, 2025, subject to the satisfaction of customary closing conditions.

Leerink Partners, Stifel and Guggenheim Securities

are acting as the bookrunning managers for the offering. Chardan and H.C. Wainwright & Co. are acting as the lead managers for

The securities described above are being offered

by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with

the U.S. Securities Exchange Commission (the "SEC") on January 7, 2025. A preliminary prospectus supplement and accompanying

prospectus relating to the offering was filed with the SEC and a final prospectus supplement and the accompanying prospectus relating

to this offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus

relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston,

Massachusetts 02109, by telephone at + 1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com, Stifel, Nicolaus &

Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone

at (415) 364-2720 or by email at syndprospectus@stifel.com or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330

Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer

to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other

jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities

laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying

prospectus forming a part of the effective registration statement.

uniQure is delivering on the promise of gene therapy

- single treatments with potentially curative results. The approvals of uniQure's gene therapy for hemophilia B - a

historic achievement based on more than a decade of research and clinical development - represent a major milestone in the field

of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of

proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease,

and other severe diseases.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain "forward-looking

statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform

Act of 1995, including, without limitation, statements regarding our expectations of market conditions, the satisfaction of customary

closing conditions and the timing of the public offering, the grant to the underwriters of an option to purchase additional securities,

the gross proceeds we expect to receive and other statements identified by words such as "estimate," "plan," "project,"

"forecast," "intend," "will," "shall," "expect," "anticipate," "believe,"

"seek," "target," "continue," "could," "may," "might," "possible,"

"potential," "predict" and similar words or expressions.

Forward-looking statements are based on management's

beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ

materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties

related to market conditions and the completion of the public offering on the anticipated terms, or at all, continued interest in our

rare disease and gene therapy portfolio, the ability to develop our product candidates and technologies, regulatory developments, the

impact of changes in the financial markets and global economic conditions, and other factors described under the heading "Risk

Factors" in uniQure's periodic securities filings with the SEC, including our Annual Report on Form 10-K filed February 28,

2024, our Quarterly Report on Form 10-Q filed November 5, 2024, the preliminary prospectus supplement filed January 7,

2025 and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties,

and other factors, you should not place undue reliance on these forward-looking statements, and uniQure assumes no obligation to update

these forward-looking statements, even if new information becomes available in the future.